The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed. -
Immune Response to Isatuximab Correlates With Clinical Response in Patients With Relapsed or Refractory Multiple Myeloma
Could myeloma-associated antibodies could one day serve as biomarkers for predicting which patients will benefit from isatuximab? -
Measurable Residual Disease: The Future of Multiple Myeloma Assessment?
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma. -
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Analysis Determines Cost Effectiveness of Various Treatment Strategies for Multiple Myeloma
Dental Issues Can Delay Treatment for Patients With Multiple Myeloma
Findings Support Routine Clinical Use of Molecular MRD Assays in Multiple Myeloma
Serum-Free Light Chain Surge Linked to Tumor Lysis Syndrome in Myeloma
Strategies for Increasing PRO Response Rates in Patients With Multiple Myeloma
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
